Agarwal Arjun: insider trades.
Agarwal Arjun reported 21 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 15 sales ($2.9M), across 1 company.
- Transactions
- 21
- Purchases (P)
- 0
- Sales (S)
- 15
- Companies
- 1
- Name as filed
- Agarwal Arjun
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | Officer · Senior Vice President, Finance | 21 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-21 | Oruka Therapeutics, Inc. | S | 533 | $95.75 | 14,219 | Form 4 |
| 2026-09-15 | Oruka Therapeutics, Inc. | S | 560 | $95.71 | 14,752 | Form 4 |
| 2026-09-11 | Oruka Therapeutics, Inc. | S | 3,000 | $91.11 | 21,771 | Form 4 |
| 2026-09-11 | Oruka Therapeutics, Inc. | M | 1,459 | $34.39 | 24,771 | Form 4 |
| 2026-09-11 | Oruka Therapeutics, Inc. | M | 8,000 | $12.5 | 23,312 | Form 4 |
| 2026-09-11 | Oruka Therapeutics, Inc. | S | 4,051 | $92.41 | 17,720 | Form 4 |
| 2026-09-11 | Oruka Therapeutics, Inc. | S | 2,208 | $93.26 | 15,512 | Form 4 |
| 2026-09-11 | Oruka Therapeutics, Inc. | S | 200 | $94.02 | 15,312 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | S | 2,100 | $104.67 | 23,212 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | M | 8,542 | $12.5 | 23,854 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | M | 1,458 | $34.39 | 25,312 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | S | 2,358 | $108.46 | 15,312 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | S | 2,142 | $107.71 | 17,670 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | S | 2,132 | $105.57 | 21,080 | Form 4 |
| 2026-08-13 | Oruka Therapeutics, Inc. | S | 1,268 | $106.63 | 19,812 | Form 4 |
| 2026-07-13 | Oruka Therapeutics, Inc. | M | 8,541 | $12.5 | 23,853 | Form 4 |
| 2026-07-13 | Oruka Therapeutics, Inc. | M | 1,458 | $34.39 | 25,311 | Form 4 |
| 2026-07-13 | Oruka Therapeutics, Inc. | S | 300 | $85.63 | 15,312 | Form 4 |
| 2026-07-13 | Oruka Therapeutics, Inc. | S | 3,743 | $84.26 | 21,268 | Form 4 |
| 2026-07-13 | Oruka Therapeutics, Inc. | S | 5,656 | $84.9 | 15,612 | Form 4 |
| 2026-07-13 | Oruka Therapeutics, Inc. | S | 300 | $83.07 | 25,011 | Form 4 |
Questions
What stock did Agarwal Arjun buy or sell?
Agarwal Arjun reported 21 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 15 sales ($2.9M), across 1 company.
Is Agarwal Arjun the same person as other filers with this name?
This page covers SEC CIK 2033974 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/agarwal-arjun-2033974.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.